GHRP-6

Mechanism

One of the original GH-releasing peptides. It triggers a strong growth hormone pulse AND significantly increases hunger. The appetite boost makes it popular for people trying to gain weight or muscle mass. It's injected subcutaneously, usually 2-3 times daily.

Effects

ENDOCRINE / GH AXIS [Tier 1 – Human Clinical]: GHRP-6 (Growth Hormone Releasing Peptide-6) is a first-generation hexapeptide ghrelin mimetic that potently stimulates GH release from the pituitary. Binds GHS-R1a (ghrelin receptor) with strong affinity. Produces robust GH pulses — typically 3-6x baseline within 15-30 minutes of injection. Also increases ACTH, cortisol (mild, transient), prolactin (mild), and importantly, ghrelin and appetite. GH/IGF-1 elevation is dose-dependent up to saturation (~2 mcg/kg). APPETITE / METABOLIC [Tier 1 – Human Clinical]: The defining feature of GHRP-6 vs other GHRPs is its potent appetite stimulation. Activates ghrelin signaling in the hypothalamus, producing intense hunger within 20-30 minutes of injection. This is a feature for underweight patients or those in caloric surplus phases, and a bug for those seeking fat loss. Gastric motility is enhanced. Some evidence of gastroprotective effects. CARDIOVASCULAR [Tier 2 – Limited Human]: GHRP-6 has demonstrated cardioprotective properties in preclinical models, reducing infarct size and improving cardiac function post-ischemia. Human data limited but early studies suggest potential benefit in heart failure. Unlike hexarelin, GHRP-6 does not interact strongly with the CD36 cardiac scavenger receptor. MUSCULOSKELETAL [Tier 2 – Limited Human]: Through GH/IGF-1 elevation, supports nitrogen retention, protein synthesis, and connective tissue repair. Effects are indirect (via GH axis) rather than direct anabolic action. Recovery enhancement and injury healing support commonly reported. NEUROLOGICAL [Tier 3 – Preclinical]: Some evidence of neuroprotective effects in animal models of brain injury and neurodegeneration. May cross the blood-brain barrier to a limited degree. Ghrelin receptor activation in the brain has implications for memory, mood, and neuroprotection.

Practitioner Guide

CLINICAL POSITIONING: GHRP-6 is the "classic" GHRP — potent, cheap, reliable, but dirty compared to newer options. The strong appetite stimulation makes it ideal for muscle-building phases, recovery from illness/surgery, or patients who struggle to eat enough. It is a poor choice for fat loss protocols due to the hunger drive. For patients who want GH optimization without appetite issues, Ipamorelin or GHRP-2 are preferred. DOSING PROTOCOLS: • Standard GH optimization: 100-200 mcg subcutaneous, 2-3x daily. Classic protocol is 100 mcg 3x/day (morning, post-workout, pre-bed). • Saturation dose: ~1 mcg/kg body weight per injection (100 mcg for 100 kg individual). Going higher does not proportionally increase GH release — you hit receptor saturation. • Timing: Inject on empty stomach (2+ hours post-meal). GH response is blunted by food, especially carbohydrates and fats. Wait 20-30 min post-injection before eating. • Pre-bed dosing: Amplifies natural nocturnal GH pulse. Most important single dose if only doing 1x/day. DESENSITIZATION — THE CRITICAL ISSUE: • GHRP-6 causes measurable receptor desensitization with continuous use. GH response diminishes by approximately 30-50% over 8-12 weeks of daily use. • Cycling protocol: 5 days on / 2 days off (weekdays on, weekends off) delays desensitization. • Full cycle: 8-12 weeks on, 4 weeks off minimum for receptor resensitization. • Desensitization is dose-dependent — lower doses (100 mcg) desensitize slower than higher doses (300 mcg). • Combining with GHRH analog (CJC-1295, Sermorelin, or Mod GRF 1-29) produces synergistic GH release and partially mitigates GHRP desensitization, as you are stimulating GH release via two separate receptor pathways. MANAGING APPETITE STIMULATION: • The hunger hits 20-30 minutes post-injection and lasts 30-60 minutes. Warn patients. • For fat loss patients (rare to use GHRP-6 here, but if needed): inject pre-bed, sleep through the hunger. • For muscle gain: exploit the hunger. Inject 30 min before largest meal. • Appetite stimulation does NOT desensitize as quickly as GH release — patients may still get ravenous even when GH response is blunting. STACKING: • GHRP-6 + Mod GRF 1-29 (CJC-1295 no DAC): The gold standard GH peptide stack. Synergistic GH release (3-5x greater than either alone). Inject both at same time, same syringe OK. • GHRP-6 + CJC-1295 DAC: DAC version provides continuous GHRH baseline, GHRP-6 provides acute GH pulses on top. See CJC-1295 DAC entry for DAC vs no-DAC debate. BLOOD WORK MONITORING: • Baseline: IGF-1, fasting glucose, fasting insulin, HbA1c, GH (optional), prolactin, cortisol AM. • 6-week check: IGF-1 (target 200-350 ng/dL for optimization, not supraphysiological), fasting glucose/insulin (watch for insulin resistance), prolactin (GHRP-6 raises it mildly — if significant elevation, switch to Ipamorelin). • 12-week: Full panel repeat. Assess for desensitization (IGF-1 dropping back toward baseline suggests receptor downregulation). SIDE EFFECTS TO MANAGE: • Intense hunger (expected, not a side effect per se — manage with timing). • Water retention/bloating in first 2 weeks (transient, GH-mediated). • Mild cortisol elevation (usually clinically insignificant). • Prolactin elevation (usually mild; if symptomatic, switch peptides). • Tingling/numbness in extremities (GH-related carpal tunnel symptoms — reduce dose).

Dosing Protocols

Contraindications & Cautions

• hard stop — Active cancer
  GHRP-6 elevates GH and IGF-1 via ghrelin receptor agonism. IGF-1 is mitogenic and may accelerate tumor growth and progression.
  Action: Do not use in patients with any active cancer. Cancer survivors should obtain oncologist clearance.
• hard stop — Pregnancy
  No human safety data during pregnancy. GH/IGF-1 elevation poses risk to fetal development.
  Action: Do not use during pregnancy. Discontinue if pregnancy is detected.
• hard stop — Breastfeeding
  No data on excretion in breast milk. Safety not established.
  Action: Do not use while breastfeeding.
• hard stop — Under 18 years of age
  GH-axis peptides are not designed for unsupervised pediatric use.
  Action: Do not provide to individuals under 18.
• requires physician — Diabetes
  GH elevation antagonizes insulin action. GHRP-6 also stimulates appetite intensely, which may complicate dietary management in diabetic patients.
  Action: Requires physician supervision. Frequent blood glucose monitoring mandatory. Monitor dietary intake.
• caution — Eating disorders
  GHRP-6 is the most potent appetite stimulator among GHRPs, causing intense hunger via ghrelin receptor activation. This can trigger binge eating episodes and complicate eating disorder recovery.
  Action: Use with extreme caution. Consider alternative GHRPs (ipamorelin) with less appetite stimulation. Requires mental health professional monitoring if history of eating disorders.

Evidence

• Preliminary evidence for an interaction between GHRP-6 and cortistatin in humans

  Arvat E, Maccario M, Di Vito L, Broglio F, Benso A, Gottero C, Papotti M, Muccioli G, Dieguez C, Casanueva FF, Deghenghi R, Camanni F, Ghigo E (2001) — Journal of Clinical Endocrinology and Metabolism — PMID: 11397847

  GHRP-6 administration in healthy human volunteers produced robust GH release and stimulated appetite through ghrelin receptor activation. The study characterized the hormonal response profile including effects on cortisol, ACTH, and prolactin, distinguishing GHRP-6 from more selective secretagogues like ipamorelin.

  moderate

• On the in vitro and in vivo activity of a new synthetic hexapeptide that acts on the pituitary to specifically release growth hormone

  Bowers CY, Momany FA, Reynolds GA, Chang D, Hong A, Chang K (1980) — Endocrinology — PMID: 6773420

  GHRP-6 was identified as a potent synthetic hexapeptide capable of specifically releasing GH from pituitary cells in vitro and in vivo. The peptide acted through a mechanism distinct from GHRH, laying the groundwork for discovery of the ghrelin receptor and development of subsequent GH secretagogues.

  moderate

Research Summary

TIER 1 (Human Clinical Trials): • Extensive human pharmacokinetic and pharmacodynamic studies dating to the 1990s. GHRP-6 is one of the most studied GH secretagogues. • Bowers et al. (1990s series): Characterized GH release kinetics — peak at 15-30 min, dose-dependent up to saturation, synergistic with GHRH. • Arvat et al. (1997): Demonstrated acute GH response of 25-50 ng/mL in healthy adults at standard doses. • Human studies confirming cortisol, prolactin, and ACTH co-release (differentiating from Ipamorelin which lacks these effects). TIER 2 (Limited Human / Strong Preclinical): • Cardiac studies in animal models showing reduced infarct size and improved post-ischemic cardiac function. • Appetite and ghrelin axis studies confirming potent orexigenic effects mediated through hypothalamic NPY/AgRP neurons. • Desensitization studies documenting GH response attenuation with chronic daily dosing (30-50% reduction over 8-12 weeks). TIER 3 (Preclinical / Mechanistic): • Neuroprotective effects in rodent models of traumatic brain injury and 6-OHDA neurodegeneration. • Gastroprotective effects via ghrelin receptor activation in gastric mucosa. • Anti-fibrotic effects in liver and cardiac tissue (animal models). EVIDENCE GAPS: No Phase III human trials for any indication. Desensitization kinetics not rigorously characterized in controlled human studies. Optimal cycling protocols based on practitioner experience rather than clinical evidence. Cardiac benefits not validated in human heart failure trials.